Trevi Therapeutics, Inc.TRVINASDAQ
Loading
SG&A Expense Growth TrendStable
Percentile Rank67
3Y CAGR+70.8%
5Y CAGR-4.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+70.8%/yr
vs -50.6%/yr prior
5Y CAGR
-4.8%/yr
Recent acceleration
Acceleration
+121.3pp
Accelerating
Percentile
P67
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 30.48% |
| 2024 | 18.62% |
| 2023 | 1.66% |
| 2022 | 6.12% |
| 2021 | -6.58% |
| 2020 | 39.08% |
| 2019 | 68.50% |
| 2018 | 102.43% |
| 2017 | 25.41% |
| 2016 | 0.00% |